Guidelines for the Management of<i>Helicobacter pylori</i>Infection in Japan: 2009 Revised Edition

Asaka, Masahiro; Kato, Mototsugu; Takahashi, Shinichi; Fukuda, Yoshihiro; Sugiyama, Toshiro; Ota, Hiroyoshi; Uemura, Naomi; Murakami, Kazunari; Satoh, Kiichi; Sugano, Kentaro

doi:10.1111/j.1523-5378.2009.00738.x

Cited by 354 publications

(233 citation statements)

References 287 publications

(374 reference statements)

Supporting

Mentioning

232

Contrasting

Order By: Relevance

“…This therapy is also strongly recommended for the treatment of H. pylori-related MALToma (5). In regions with a high incidence of gastric adenocarcinoma, the eradication of H. pylori is advocated as a preventative measure (6,7).…”

mentioning

confidence: 99%

“…In most international guidelines (6)(7)(8)(9), standard triple therapy consisting of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin (or metronidazole) for 7 to 14 days is recommended as the first-line therapy of H. pylori infection, especially in areas of low clarithromycin resistance (Ͻ10%). Recently, the eradication rates of standard triple therapy have declined to Ͻ80% in many countries, largely owing to emerging organism resistances (10)(11)(12)(13).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection

Hsu

Chen

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

e With the rising prevalence of antimicrobial resistance, the failure rate of the standard triple therapy for Helicobacter pylori infection is increasing. Sequential therapy and concomitant therapy have been recommended to replace standard triple therapy for H. pylori eradication in regions with high clarithromycin resistance. The aim of this prospective, randomized, and controlled study was to simultaneously assess the efficacies of 10-day sequential and 7-day concomitant therapies versus a 7-day standard triple therapy for treating H. pylori infection. Consecutive H. pylori-infected subjects were randomly assigned to a 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin, and metronidazole for a further 5 days), or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin, and metronidazole for 7 days). H. pylori status was confirmed 6 weeks after therapy. Three hundred seven H. pylori-infected participants were randomized to receive triple (n ‫؍‬ 103), sequential (n ‫؍‬ 102), or concomitant (n ‫؍‬ 102) therapies. The eradication rates by an intention-to-treat analysis in the three treatment groups were 81.6% (95% confidence interval [CI], 74.1% to 89.0%), 89.2% (95% CI, 83.2% to 95.2%), and 94.1% (95% CI, 89.5% to 98.7%). The seven-day concomitant therapy had a higher eradication rate than did the 7-day triple therapy (difference, 12.5%; 95% CI, 3.7% to 21.3%). There were no significant differences in the eradication rates between the sequential and standard triple therapies. All three treatments exhibited similar frequencies of adverse events (8.7%, 8.8%, and 13.7%, respectively) and drug compliance (99.0%, 98.0%, and 100.0%, respectively). In conclusion, the seven-day concomitant therapy is superior to the 7-day standard triple therapy for H. pylori eradication. Additionally, it is less complex than the 10-day sequential therapy because the drugs are not changed halfway through the treatment course. (This study has been registered at ClinicalTrials.gov under registration no. NCT1769365.)

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection

Hsu

Chen

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…[8][9][10][11][12] HpSA is a simple, easy and useful method which uses polyclonal or monoclonal antibody-based techniques 6,10-12 and is recommended for confirming both diagnosis and eradication. 6,13 HpSA is simple, fast and inexpensive analytical process which could be easily obtained at home (only stool sample is needed) and does not require laboratory attendance or fasting. [10][11][12] The H. pylori infection prevalence is very high among the Iranian general population.…”

mentioning

confidence: 99%

Role of Helicobacter Pylori stool antigen test in the diagnosis of Helicobacter Pylori infection

Pourlak¹,

Shokouhi²,

Vahedi³

2017

J Anal Res Clin Med

View full text Add to dashboard Cite

Stool Antigen Test, AccuracyHelicobacter pylori (H. pylori) infection is common in developing countries. There are various invasive and non-invasive methods for diagnosing H. pylori infection. Stool antigen test is a new non-invasive method to diagnose H. pylori infection. In this study we evaluated the diagnostic accuracy of HpSA for H. pylori infection in patients with gastrointestinal (GI) complaints.Sixty patients including 28 men and 32 women with mean age of 49.2 ± 19.8 years undergoing diagnostic endoscopy with 30 positive and 30 negative rapid urease test (RUT) and histology results for H. pylori infection were evaluated. H. pylori stool antigen test (HpSA) was measured in these patients and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for HpSA were calculated.Among 31 positive HpSA results, 2 were negative in RUT and histology and among 29 negative HpSA results, 1 was positive in RUT and histology results. Sensitivity, specificity, PPV, NPV and accuracy for HpSA in diagnosing H. pylori infection were 96.67%, 93.33%, 93.55%, 96.55% and 95%, respectively.Although the sensitivity and specificity of the HpSA are evaluated in a relatively small sample size, these results showed that HpSA is a useful test in diagnosing H. pylori infection in patients with upper GI complaints.

show abstract

“…Until September 2015, the scientific community has recognized three hematologic diseases as extragastric manifestations of H. pylori infection: iron deficiency [21][22][23][24][25][26][27][28][29][30], vitamin B 12 deficiency [27,29], and immune thrombocytopenia (ITP) [21,[23][24][25][26][27][28][29][30][31]. These will be carefully analyzed in the following subsections.…”

Section: Hematological Diseases Recognized As Related To H Pylorimentioning

confidence: 99%

“…The first decade of the twenty-first century provided most of the studies that currently support the five meta-analyses associating H. pylori infection with iron deficiency and the resolution of disease following infection eradication [46][47][48][49][50] in children [51][52][53][54][55][56][57][58][59][60], in pubescent males and females [61,62], in prepubertal girls [63], in adult men and women [40,45,[64][65][66][67][68][69][70][71][72][73][74][75], in seniors [76], in pregnant women [63], and in non-pregnant women [77]. In addition, these studies have provided scientific support to the different consensus and guidelines for incorporating iron deficiency into the medical management of H. pylori infection as an extragastric manifestation and indication for eradication [21][22][23][24][25][26][27][28][29][30].…”

Section: H Pylori and Iron Deficiencymentioning

confidence: 99%

Helicobacter pylori and Hematologic Diseases

Campuzano-Maya¹

2016

Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview

View full text Add to dashboard Cite

Helicobacter pylori infection is the most common infection of the human species, with developing countries displaying a marked disadvantage in contrast to developing countries. While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal and gastric peptic ulcers. Since the discovery that gastric mucosa could be colonized by bacteria, evidence of greater than 50 extragastric manifestations has been reported, linking H. pylori infection and the development of diseases associated with cardiology, dermatology, endocrinology, obstetrics and gynecology, hematology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, and pediatrics. This chapter presents the extragastric manifestations of H. pylori infection expressed through hematologic diseases; particularly those included in the international consensus, and discusses guidelines for the management of H. pylori infection, such as iron deficiency, vitamin B 12 (cobalamin) deficiency, and immune thrombocytopenia. Other manifestations reviewed include immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias, such us monoclonal gammopathy of undetermined significance, multiple myeloma, and Henoch-Schönlein purpura.

show abstract

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

Abstract: The revised Japanese guidelines for H. pylori are based on scientific evidence and avoid the administrative restraints that applied to earlier versions.

Cited by 354 publications

References 287 publications

Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection

Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection

Role of Helicobacter Pylori stool antigen test in the diagnosis of Helicobacter Pylori infection

Helicobacter pylori and Hematologic Diseases

Contact Info

Product

Resources

About